Thomas E. Keane, MD, presented “The PRONOUNCE Trial: The Cardiovascular Safety of Degarelix vs. Leuprolide” for the Grand Rounds in Urology audience in November 2021.

How to cite: Keene, Thomas E. The PRONOUNCE Trial: The Cardiovascular Safety of Degarelix vs. Leuprolide.” November 2021. Accessed Jun 2024.

The PRONOUNCE Trial: The Cardiovascular Safety of Degarelix vs. Leuprolide

Thomas E. Keane, MD, Professor and Chairman of the Department of Urology at the Medical University of South Carolina in Charleston, summarizes the design and results of the PRONOUNCE trial on the cardiovascular safety of degarelix versus leuprolide in patients with advanced prostate cancer. The PRONOUNCE trial looked at whether there was a difference in adverse cardiovascular effects between patients treated with a gonadotropin-releasing hormone (GnRH) antagonist (degarelix) and a GnRH agonist (leuprolide). Dr. Keane says that he believes that the different mechanisms of action of the two kinds of drugs logically seem to favor the GnRH antagonist as less likely to cause cardiovascular complications, although he notes that this remains a contentious topic. He observes that while the PRONOUNCE did find some advantage to degarelix over leuprolide, it was significantly less in this trial compared to others that have compared agonists and antagonists, including the HERO trial. Dr. Keane suggests this may be due to the fact that all patients in the PRONOUNCE trial were under the supervision of a cardiologist for the duration of the trial. He concludes that, although PRONOUNCE was a prospective trial that was cut short and only included 545 out of 900 planned patients, its results are suggestive and will hopefully help lead to further research.  

For more on cutting-edge treatments for advanced prostate cancer, check out the collection page for the 31st International Prostate Cancer Update, held in Snowbird, Utah, in July 2021.